Neuroregulatory Comparison Matrix
Semax, Selank, DSIP and Kisspeptin-10 share a catalogue category, not a common proven mechanism. Semax and Selank are synthetic peptide research entities with distinct parent-sequence relationships; DSIP has a historically uncertain biological story. Kisspeptin-10 is a KISS1-derived decapeptide studied at KISS1R/GPR54, a distinct receptor system. Comparing these four materials requires explicit receptor, model and endpoint labels.
Neuroregulatory research matrix
| Feature | Semax | Selank | DSIP | Kisspeptin-10 |
|---|---|---|---|---|
| Research identity | ACTH(4-7)-derived synthetic peptide with PGP extension | Tuftsin-derived synthetic peptide with PGP extension | Named short peptide with unresolved historical physiological role | KISS1-derived, C-terminal decapeptide; KISS1R/GPR54 ligand in experimental systems |
| Representative evidence | Region-specific neurotrophin and ischaemia-model gene-expression studies | GABAergic and immune-related gene-expression studies with model/co-exposure dependence | Sleep-related studies with weak/inconsistent controlled evidence and an unresolved review literature | Receptor signalling and mouse GnRH-neuron experiments; distinct from sleep and GABAergic assays |
| Main interpretation trap | “Raises BDNF” ignores region-specific increases and decreases | “GABA agonist” overstates indirect/model-dependent gene-expression data | The name “sleep-inducing” should not be treated as proof of a reliable sleep effect | KISS1R signalling cannot be treated as a clinical endocrine outcome or evidence about a supplied RUO lot |
| Catalogue | Semax 10mg | Selank 10mg | DSIP 10mg | Kisspeptin-10 10mg |
Semax: molecular responses vary by brain region and injury context
Semax studies report neurotrophin and inflammatory-gene-expression changes in rat models. These are molecular endpoints, not proof of cognitive enhancement or clinical neuroprotection. See the Semax research overview.
Selank: model and co-exposure matter
Selank-related gene-expression responses differ between rat brain, cultured neuroblastoma cells and mouse spleen. In one cell model Selank alone did not reproduce the GABAergic transcript changes inferred from other experiments. See the Selank research overview.
DSIP: uncertainty is part of the evidence
A major review described the DSIP “sleep factor” hypothesis as poorly documented and unresolved. Controlled human insomnia studies also reported weak or limited effects rather than a decisive sleep benefit. The correct research framing therefore retains uncertainty rather than treating the peptide’s name as its established function.
What the controlled DSIP literature actually found: A double-blind study of 16 chronic-insomnia participants reported some weak objective sleep differences, but no consistent subjective improvement; the authors considered major therapeutic benefit unlikely. An earlier double-blind crossover study also reported several sleep measures without a convincing difference from baseline/placebo. Small, mixed human sleep observations should not be presented as proof of a general sleep mechanism or product efficacy. Double-blind study, PMID 1299794; Monti et al., 1987, PMID 3583493.
Kisspeptin-10: a different signalling question
Kisspeptin-family peptides are studied as ligands at GPR54/KISS1R. Kotani et al. (2001) established receptor signalling for KiSS1-derived ligands in defined cellular systems; Messager et al. (2005) investigated kisspeptin and GnRH-neuron signalling in mouse models. Those studies do not mean every kisspeptin isoform or length is analytically identical, nor do they establish clinical outcomes or the specification of Core Research Kisspeptin-10 10mg. It belongs in this matrix as a separate KISS1R question, not a synonym for Semax, Selank or DSIP.
How to use this comparison
- Identify the exact peptide entity used in the source.
- Separate gene-expression, receptor, behavioural and sleep endpoints.
- State whether the model is cell, animal or human experimental research.
- Retain null/weak findings rather than reporting only positive studies.
- Use lot documentation to establish the supplied product identity.
Research-use boundary
This page does not compare anxiety, sleep, focus, memory, cognition or performance outcomes for personal use and does not provide dosing or administration guidance. Core Research materials are supplied for laboratory research only.